Nanobiotix S.A. (NASDAQ:NBTX) Sees Significant Drop in Short Interest

Posted by Tech Dows on Mar 29th, 2025

Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 9,200 shares, a decrease of 68.6% from the February 28th total of 29,300 shares. Based on an average daily trading volume, of 20,100 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.0% of the company’s shares are sold short.

Nanobiotix Stock Up 1.9 %

Shares of NASDAQ NBTX traded up $0.07 during trading hours on Friday, reaching $3.63. The stock had a trading volume of 1,137 shares, compared to its average volume of 21,594. The business’s fifty day moving average price is $3.57 and its two-hundred day moving average price is $3.85. Nanobiotix has a 52-week low of $2.76 and a 52-week high of $7.51.

Institutional Investors Weigh In On Nanobiotix

Hedge funds have recently made changes to their positions in the company. OLD Mission Capital LLC purchased a new position in shares of Nanobiotix during the fourth quarter valued at $139,000. Geode Capital Management LLC bought a new position in shares of Nanobiotix during the fourth quarter valued at approximately $29,000. Jane Street Group LLC bought a new stake in Nanobiotix during the 4th quarter valued at $73,000. Finally, Millennium Management LLC purchased a new position in shares of Nanobiotix in the 4th quarter valued at $39,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, UBS Group raised shares of Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Read Our Latest Analysis on NBTX

About Nanobiotix

(Get Free Report)

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.